October 2016: Seizing the Commercial Opportunity from Big Data in Life Sciences

Pfizer and J&J supply chain experts on why health authorities now ask not just whether your quality systems work — but how fast you can adapt.

As Japan prices take on greater global significance, disciplined launch strategy can help pharma companies capture the full value of innovation.

Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.

Social listening can help medical affairs and medical information teams identify knowledge gaps, strengthen scientific exchange and respond to changing stakeholder needs faster and at greater scale.

Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.

Shionogi is acquiring IntraBio for $2 billion, Gate Bioscience expands its collaboration with Eli Lilly, and Alector licenses Al050 to Genentech.

The future of engagement won’t be defined by how much information reaches health care professionals, but by how precisely it supports the decision at hand.

Why effective RWD linkage starts with a specific research objective — and how tokenization, clean rooms, and AI make it possible.